Sugi Predict

Sugi Predict / Compounds / SCHEMBL371568

SCHEMBL371568

SCHEMBL371568

COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CCC4)cc3F)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 16/20 0.78
▸ KDR P35968 11/20 0.78
▸ FLT1 P17948 2/20 0.78
▸ FLT4 P35916 2/20 0.78
▸ AURKA O14965 2/20 0.78
▸ FLT3 P36888 2/20 0.78
▸ PLK4 O00444 1/20 0.78
▸ STK25 O00506 1/20 0.78
▸ CIT O14578 1/20 0.78
▸ CHUK O15111 1/20 0.78
▸ MUSK O15146 1/20 0.78
▸ EPHB6 O15197 1/20 0.78
▸ MAPK13 O15264 1/20 0.78
▸ MAP3K13 O43283 1/20 0.78
▸ DAPK3 O43293 1/20 0.78
▸ MAP3K7 O43318 1/20 0.78
▸ RIPK2 O43353 1/20 0.78
▸ JAK2 O60674 1/20 0.78
▸ ROCK2 O75116 1/20 0.78
▸ PAK3 O75914 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371662 0.97 MET (0.82) METKDRFLT1FLT4AURKA
SCHEMBL371849 0.97 MET (0.82) METKDRFLT1FLT4AURKA
SCHEMBL29693459 0.97 MET (0.82) METKDRFLT1FLT4AURKA
SCHEMBL24444603 0.95 MET (0.72) METKDRFLT1FLT4AURKA
SCHEMBL24444623 0.94 MET (0.69) METKDRFLT1FLT4AURKA
SCHEMBL29693460 0.93 MET (0.73) METKDRFLT1FLT4AURKA
SCHEMBL371716 0.93 MET (0.73) METKDRFLT1FLT4AURKA
SCHEMBL24444601 0.93 MET (0.75) METKDRFLT1FLT4AURKA
SCHEMBL372042 0.92 MET (0.71) METKDRFLT1FLT4AURKA
SCHEMBL29693532 0.92 MET (0.73) METKDRFLT1FLT4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120184523-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-07-19 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20110077233-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2011-03-31 — — US claimed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT1 2/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT1 2/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT1 2/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT1 2/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT1 2/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS MET 312/4885KDR 1023/4885FLT1 1004/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885KDR 5/4885FLT1 3/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT1 2/4885
US-20120184523-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885FLT1 3/4885
US-20110077233-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885FLT1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.